Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like New insights into mTOR pathway offer hope for diabetic nephropathy treatment February 25, 2025 HIV vaccine study marks breakthrough in targeting broad immune responses May 15, 2025 Northwestern scientists identify key genes behind Parkinson’s development April 11, 2025